Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Abbvie Inc (ABBV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 149,625,024
  • Shares Outstanding, K 1,514,270
  • Annual Sales, $ 28,216 M
  • Annual Income, $ 5,309 M
  • 36-Month Beta 1.56
  • Price/Sales 5.27
  • Price/Cash Flow 14.92
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate 2.01
  • Number of Estimates 9
  • High Estimate 2.04
  • Low Estimate 1.94
  • Prior Year 1.41
  • Growth Rate Est. (year over year) +42.55%

Price Performance

See More
Period Period Low Period High Performance
1-Month
86.76 +13.89%
on 07/20/18
99.15 -0.34%
on 08/17/18
+3.40 (+3.56%)
since 07/17/18
3-Month
86.76 +13.89%
on 07/20/18
107.25 -7.87%
on 05/21/18
-6.51 (-6.18%)
since 05/17/18
52-Week
69.47 +42.23%
on 08/18/17
125.86 -21.49%
on 01/26/18
+28.96 (+41.46%)
since 08/17/17

Most Recent Stories

More News
Global Blood The is Among the Companies in the Biotechnology Industry with the Best Relative Performance (GBT , NVTA , ABBV , CLVS , VNDA )

Here are the top 5 stocks in the Biotechnology industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

NVTA : 10.21 (-2.58%)
GBT : 49.30 (-1.30%)
ABBV : 98.81 (+0.60%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AbbVie Inc. - ABBV

NEW YORK, NY / ACCESSWIRE / August 15, 2018 / is investigating claims on behalf of investors of AbbVie Inc. ("AbbVie" or the "Company") (NYSE: ABBV). Such investors are advised to contact Robert S. Willoughby...

ABBV : 98.81 (+0.60%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AbbVie Inc. - ABBV

Pomerantz LLP is investigating claims on behalf of investors of AbbVie Inc. ("AbbVie" or the "Company") . Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com [https://prnnj3-irisxe11.prnewswire.local/ewebeditor/]...

ABBV : 98.81 (+0.60%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AbbVie Inc. - ABBV

Pomerantz LLP is investigating claims on behalf of investors of AbbVie Inc. ("AbbVie" or the "Company") (NYSE: ABBV). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com...

ABBV : 98.81 (+0.60%)
Watch for Abbvie Inc to Potentially Pullback After Gaining 1.36% Yesterday

Abbvie Inc (NYSE:ABBV) traded in a range yesterday that spanned from a low of $95.81 to a high of $97.58. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $96.74...

ABBV : 98.81 (+0.60%)
Top Analyst Reports: Mastercard, AbbVie, Twenty-First Century Fox & More

Top Analyst Reports: Mastercard, AbbVie, Twenty-First Century Fox & More

FOXA : 45.38 (-0.63%)
MA : 203.21 (-0.19%)
SCHW : 50.90 (-0.45%)
FTV : 80.25 (-0.11%)
ABBV : 98.81 (+0.60%)
ALXN : 116.00 (-1.09%)
CLASS ACTION UPDATE for FPI and ABBV: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have...

ABBV : 98.81 (+0.60%)
FPI : 7.03 (+0.86%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AbbVie Inc. - ABBV

NEW YORK, NY / ACCESSWIRE /August 8, 2018 / is investigating claims on behalf of investors of AbbVie Inc. ("AbbVie" or the "Company") (NYSE: ABBV). Such investors are advised to contact Robert S. Willoughby...

ABBV : 98.81 (+0.60%)
Mylan (MYL) Q2 Earnings and Revenues Miss, Guidance Cut

Mylan is expected to loose ground after its second-quarter results miss estimates. The cut in guidance is disappointing as well.

MYL : 38.15 (+0.79%)
ABBV : 98.81 (+0.60%)
RHHBY : 30.1200 (+0.57%)
GSK : 41.25 (+1.03%)
SHAREHOLDER ALERT: MRCY HAIR TAL REVG GLCNF GLNCY FPI GOGO ABBV: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request...

GOGO : 4.57 (+0.88%)
REVG : 16.97 (-0.64%)
HAIR : 1.81 (-1.09%)
GLCNF : 3.9075 (+1.10%)
ABBV : 98.81 (+0.60%)
TAL : 31.12 (-4.45%)
FPI : 7.03 (+0.86%)
MRCY : 50.06 (+0.93%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade ABBV with:

Business Summary

AbbVie is a global, research-based biopharmaceutical company. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company's mission is to use its expertise, dedicated people and unique approach to innovation...

See More

Key Turning Points

2nd Resistance Point 100.86
1st Resistance Point 99.83
Last Price 98.81
1st Support Level 97.10
2nd Support Level 95.40

See More

52-Week High 125.86
Fibonacci 61.8% 104.32
Last Price 98.81
Fibonacci 50% 97.67
Fibonacci 38.2% 91.01
52-Week Low 69.47

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar